Tolcapone improves motor function in parkinsonian patients with the 'wearing-off' phenomenon: A double-blind, placebo-controlled, multicenter trial

Neurology

Volumn 49, Issue 4, 1997, Pages 1066-1071

  Rajput, A H ^a   Martin, W ^b   Saint Hilaire, M H ^c   Dorflinger, E ^d   Pedder, S ^d  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; TOLCAPONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030669245     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.4.1066     Document Type: Article

References (34)

1. Cedarbaum JM. Clinical pharmacokinetics of antiparkinsonian drugs. Clin Pharmacokinet 1987;13:141-178.
2. Rinne UK. Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand Suppl 1983; 95:19-26.
3. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681.
4. Mouradian MM, Chase TN. Levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:378-385.
5. Fahn S. Adverse effects of levodopa in Parkinson's disease. In: Calne DB, ed. Drugs for the treatment of Parkinson's disease. Berlin: Springer-Verlag, 1989:385-409.
6. Nutt JG. Levodopa: rational and irrational pharmacology. Ann Neurol 1994;36:4-5.
7. Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987;22:535-540.
8. Mouradian MM, Juncos JL, Fabbrini G, Chase TN. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 1987;22:475-479.
9. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
10. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994; 36:27-31.
11. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanism. Part I. Ann Neurol 1988;24: 366-371.
12. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;43(suppl 6):S23-S27.
13. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
14. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994;44(suppl 6): S15-S18.
15. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
16. Zürcher G. Colzi A, Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl 1990;32:375-380.
17. Da Prada M, Zürcher G, Kettler R, Colzi A. New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592. Adv Behav Biol 1991;39: 723-732.
18. Borgulya J, Da Prada M, Dingemanse J, Scherschlicht R, Schläppi B, Zürcher G. Ro 40-7592: catecholamine-O-methyltransferase (COMT) inhibitor. Drugs Future 1991;16: 719-721.
19. Zürcher G, Dingemanse J, Da Prada M. Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: preclinical and clinical findings. In: Agnoli A, Campanella G, eds. New developments in therapy of Parkinson's disease. Rome: John Libbey, 1991:37-43.
20. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995;57:508-517.
21. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-262.
22. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-dopa pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 1995;18: 333-337.
23. Limousin P, Pollak P, Pfefen JP, Tournier-Gervason CL, Dubuis R, Perret JE. Acute administration of levodopabenserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995;18:258-265.
24. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1994;44:2685-2688.
25. Kurth MC, Adler CH, St. Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87.
26. Dorflinger EE, Rajput A, Martin W, et al. Multicenter evaluation of tolcapone (Tasmar) when given together with levodopa to Parkinson disease patients who exhibit end-of-dose wearing-off. Neurology 1996;46(suppl):A474-A475.
27. Thuro H. COMT inhibition with tolcapone [in German]. Nervenarzt 1996;67(suppl):1-8.
28. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsant TL, ed. Quantification of neurological deficit. Woburn, MA: Butterworths, 1989:285-309.
29. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
30. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, eds. Third Symposium on Parkinson's Disease. Edinburgh: E & S Livingstone, 1969:152-157.
31. Neter J, Wassermann W, Kutner MH. Applied linear statistical models. 2nd ed. Homewood, IL: Irwin, 1985.
32. Budde M, Bauer P. Multiple test procedures in clinical dose finding studies. J Am Stat Assoc 1989;84:792-796.
33. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
34. Agresti A. Categorical data analysis. New York: John Wiley & Sons, 1990.